Approval · Notice of Compliance 34825 · 2025
RABEPRAZOLE: Notice of Compliance 34825
Issued February 12, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34825
- Date
- February 12, 2025
- Company
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Administrative: Update to labelling (to match Licensor)
- Canadian reference product
- PARIET (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RABEPRAZOLE | Not yet assigned | — |
Medicinal ingredients
- RABEPRAZOLE SODIUM 10 MG per TAB
- RABEPRAZOLE SODIUM 20 MG per TAB